Predictive value of STMN1 gene promoter polymorphism −2166T>C in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbineReportar como inadecuado




Predictive value of STMN1 gene promoter polymorphism −2166T>C in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Cancer Chemotherapy and Pharmacology

, Volume 76, Issue 3, pp 621–629

First Online: 29 July 2015Received: 19 March 2015Accepted: 15 July 2015DOI: 10.1007-s00280-015-2831-7

Cite this article as: Mlak, R., Krawczyk, P., Ciesielka, M. et al. Cancer Chemother Pharmacol 2015 76: 621. doi:10.1007-s00280-015-2831-7

Abstract

PurposeThe combination of platinum compounds and vinorelbine is often used as a first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer NSCLC, without activating EGFR mutations and ALK rearrangement. Unfortunately, less than half of the patients benefit from chemotherapy. Moreover, majority of patients are exposed to a number of side effects of chemotherapy. Stathmin-1 STMN1, oncoprotein 18 affects significantly microtubule dynamics and formation of the mitotic spindle. Therefore, the change in the STMN1 gene may be a potential predictive factor of response to treatment regimens containing a cytostatics-disrupting microtubule dynamics vinca alkaloids and taxoids. The aim of the study was to determine the relationship between a single nucleotide polymorphism SNP of the promoter of STMN1 gene −2166T>C and the effectiveness of chemotherapy based on platinum compounds and vinorelbine in patients with NSCLC.

MethodsThe investigated population consisted of 110 locally advanced or metastatic NSCLC patients treated with first-line chemotherapy, based on platinum compounds and vinorelbine. SNP was determined by SNaPshot™ PCR in DNA isolated from peripheral blood leukocytes.

ResultsThe median progression-free survival PFS was significantly shorter in carriers of TT genotype of the STMN1 gene compared with patients with CC or CT genotypes 2.75 vs. 6.5 months; p = 0.0033; HR 5.91, 95 % CI 1.81–19.33. Evaluated SNP did not significantly affect the response to treatment and the overall survival of the patients.

ConclusionRare TT genotype of STMN1 gene may be an unfavorable predictive factor of chemotherapy based on platinum compounds and vinorelbine, in patients with NSCLC.

KeywordsNon-small cell lung cancer Polymorphism STMN1 Chemotherapy  Download fulltext PDF



Autor: Radosław Mlak - Paweł Krawczyk - Marzanna Ciesielka - Iwona Homa - Tomasz Powrózek - Monika Prendecka - Piotr Kozioł -

Fuente: https://link.springer.com/







Documentos relacionados